Shenyang Sinqi Pharmaceutical Co., Ltd (SHE: 300573), a pharmaceutical company based in China, has received clinical trial approval from the National Medical Products Administration (NMPA) for its therapeutic biologic, SQ-22031 eye drops. This Category 1 therapeutic biologic is intended for the treatment of dry eye syndrome and neurotrophic keratitis, with the latter being a condition recognized in China’s second batch of rare diseases. Comprehensive studies on SQ-22031, encompassing pharmacology, non-clinical pharmacology, and toxicology, have yielded results that underscore the product’s favorable safety profile and potential clinical development value.- Flcube.com
Clinical trial approval / initiation Ophthalmology Rare / orphan disease drugs SHE: 300573 Sinqi Pharmaceutical
Recent news:
-
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement -
Abbott Laboratories' Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment -
Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy -
Genmab's Tivdak Approved in Japan for Advanced Cervical Cancer Treatment -
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
